Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes
Overview[ - collapse ][ - ]
Purpose | This trial is conducted in Europe. The aim of this trial is to compare two NN5401 (SIAC, insulin degludec/insulin aspart) formulations with each other and with insulin glargine, all in combination with metformin in insulin naive subjects with type 2 diabetes. |
---|---|
Condition | Diabetes Diabetes Mellitus, Type 2 |
Intervention | Drug: insulin degludec/insulin aspart Drug: insulin degludec/insulin aspart Drug: insulin glargine Drug: metformin |
Phase | Phase 2 |
Sponsor | Novo Nordisk A/S |
Responsible Party | Novo Nordisk A/S |
ClinicalTrials.gov Identifier | NCT00614055 |
First Received | January 30, 2008 |
Last Updated | November 7, 2013 |
Last verified | November 2013 |
Tracking Information[ + expand ][ + ]
First Received Date | January 30, 2008 |
---|---|
Last Updated Date | November 7, 2013 |
Start Date | January 2008 |
Estimated Primary Completion Date | July 2008 |
Current Primary Outcome Measures | Change in Glycosylated Haemoglobin (HbA1c) [Time Frame: Week 0, Week 16] [Designated as safety issue: No] |
Current Secondary Outcome Measures |
|
Descriptive Information[ + expand ][ + ]
Brief Title | Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes |
---|---|
Official Title | A 16 Week Randomised, Open Labelled, 3 Armed, Parallel Group, Treat-to-target Trial Comparing Once Daily Injection of SIAC 30 (B), SIAC 45 (B) and Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes Failing on OAD Treatment |
Brief Summary | This trial is conducted in Europe. The aim of this trial is to compare two NN5401 (SIAC, insulin degludec/insulin aspart) formulations with each other and with insulin glargine, all in combination with metformin in insulin naive subjects with type 2 diabetes. |
Detailed Description | Not Provided |
Study Type | Interventional |
Study Phase | Phase 2 |
Study Design | Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment |
Condition |
|
Intervention | Drug: insulin degludec/insulin aspart Formulation 1: Treat-to-target dose titration scheme, injection s.c., once daily Drug: insulin degludec/insulin aspart Formulation 2: Treat-to-target dose titration scheme, injection s.c., once daily Drug: insulin glargine Treat-to-target dose titration scheme, injection s.c., once daily Drug: metformin Tablets, 1500-2000 mg/day |
Study Arm (s) |
|
Recruitment Information[ + expand ][ + ]
Recruitment Status | Completed |
---|---|
Estimated Enrollment | 178 |
Estimated Completion Date | July 2008 |
Estimated Primary Completion Date | July 2008 |
Eligibility Criteria | Inclusion Criteria: - Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject.) - Insulin naïve type 2 diabetes subjects (as diagnosed clinically) for at least 3 months (no previous insulin treatment or previous short term insulin treatment maximum 14 days within the last 3 months) - Treatment with one or two oral anti-diabetic drugs (OADs): metformin, sulfonylurea, other insulin secretagogue (e.g. repaglinide, nateglinide), alpha-glucosidase inhibitors for at least 2 month at a stable maximum tolerated dose or at least half maximum allowed dose according to locally approved summary of product characteristics (SPC) - HbA1c, 7.0 - 11.0 % (both inclusive) - Body Mass Index (BMI), 25.0 - 37.0 kg/m^2 (both inclusive) Exclusion Criteria: - Metformin contraindication according to local practice - Thiazolidinedione (TZD) treatments within the previous three months prior to Visit 1 - Any systemic treatment with products, which in the investigator's opinion could interfere with glucose or lipid metabolism (e.g. systemic corticosteroids) within 3 months prior to randomisation - Subject has a clinically significant, active (during the past 12 months) disease of the gastrointestinal, pulmonary, neurological, genitourinary, or haematological system that, in the opinion of the investigator, may confound the results of the trial or pose additional risk in administering trial product |
Gender | Both |
Ages | 18 Years |
Accepts Healthy Volunteers | No |
Contacts | Not Provided |
Location Countries | France, Germany, Norway, Romania, Spain |
Administrative Information[ + expand ][ + ]
NCT Number | NCT00614055 |
---|---|
Other Study ID Numbers | NN5401-1791 |
Has Data Monitoring Committee | No |
Information Provided By | Novo Nordisk A/S |
Study Sponsor | Novo Nordisk A/S |
Collaborators | Not Provided |
Investigators | Study Director: Benedikte J. Lertoft, DVM Novo Nordisk A/S |
Verification Date | November 2013 |
Locations[ + expand ][ + ]
France | Venissieux, France, 69200 |
---|---|
Germany | Neuwied, Germany, 56564 |
Norway | Kongsvinger, Norway, 2212 |
Romania | Bucharest, Romania, 011234 |
Spain | Partida de Bacarot, Spain, 03114 |